Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today the results of a Phase 1 study, which reported that PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin (325 mg) and immediate-release omeprazole (40 mg), showed no ex vivo drug-drug interaction with clopidogrel when administered 10 hours apart in healthy patients, based on the study's pre-specified analysis.

15 Nov 2010

PPIs, antiplatelet drugs can help treat CV disease patients at high risk of upper GI bleeding

Using proton pump inhibitors and antiplatelet drugs (thienopyridines) together is an appropriate way of treating patients with cardiovascular disease who are at high risk of upper gastrointestinal bleeds, despite recent concerns about an adverse interaction between these two types of drugs, according to an Expert Consensus Document released jointly today by the American College of Cardiology Foundation, the American College of Gastroenterology, and the American Heart Association.

10 Nov 2010

Researchers to determine levels of stroke risk in patients with narrowed brain arteries

Neurological researchers at Rush University Medical Center are part of a multicenter, National Institutes of Health (NIH) study to determine the levels of stroke risk and stroke recurrence in patients with narrowed brain arteries.

10 Nov 2010

Research Roundup: Basing insurance on results, not cost; Americans skeptical of public health efforts; seniors' comprehensive care

Copayment Reductions Generate Greater Medication Adherence In Targeted Patients. As health care costs have increased, some patients have sought to save money by cutting down on their medications.

8 Nov 2010

Eliminating copayments for high-value prescription drugs improves employees' adherence to treatment regimens

An initiative by the U. S. technology company Pitney Bowes to make medications of proven value less expensive for their employees succeeded in stabilizing employees' adherence to their treatment regimens, according to a Commonwealth Fund-supported study published in this month's Health Affairs.

3 Nov 2010

Study finds increasing dosage of blood thinners can help cardiovascular disease patients with genetic defect

Cardiovascular disease patients who have a genetic defect that makes them less responsive to blood thinners may be helped with an increased dosage, according to results of an innovative pilot study led by a cardiologist at The University of Texas Health Science Center at Houston (UTHealth).

2 Nov 2010

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Aspirin reduces risk of death from prostate cancer

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

26 Oct 2010

Dual antiplatelet therapy study expanded into Australia and New Zealand

The Harvard Clinical Research Institute (HCRI) announced today that the DAPT Study has expanded into Australia and New Zealand. Professor Ian Meredith, MBBS, Ph.D., interventional cardiologist at MonashHeart in Melbourne, Australia and National Coordinating Investigator for the DAPT Study in Australia, was the first Pacific Rim investigator to enroll patients into the study.

26 Oct 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

New guidelines feature various key updates for stroke or TIA survivors

Treating metabolic syndrome and undergoing carotid angioplasty may prevent recurrent stroke or transient ischemic attack, according to revised American Heart Association/American Stroke Association guidelines.

22 Oct 2010

CyDex terminates joint development agreement on Captisol-enabled clopidogrel with Prism Pharmaceuticals

CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.

13 Oct 2010

New genetic screening program to reduce risk associated with Plavix

Beginning this month, all patients undergoing cardiac catheterization at Vanderbilt University Medical Center will be tested for a genetic variation that can affect their response to Plavix, the most commonly prescribed clot-preventing drug for heart patients and one of the most commonly prescribed drugs worldwide.

29 Sep 2010

Biodegradable polymers represent future of stent design

Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

21 Sep 2010

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

A study evaluating the level of platelet aggregation achieved after switching from Plavix (clopidogrel) 75 mg once-daily maintenance dosing plus aspirin to Effient(prasugrel) 10 mg once-daily maintenance dosing (MD) in patients with acute coronary syndrome (ACS) was published today in the Journal of the American College of Cardiology.

14 Sep 2010

Ticagrelor exhibits potential for prevention of heart attacks

New findings from a major drug trial have brought experts a step closer to developing a drug which could prevent thousands of British deaths from heart attacks.

13 Sep 2010

Accumetrics secures $24 million in capital infusion

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that it has completed its capital financing efforts, the first round of which was announced in the Fall of 2009.

2 Sep 2010

Using clopidogrel, PPIs increases cardiac damage risk: Study

Patients with coronary artery disease undergoing stent implantation are often prescribed the antiplatelet drug, clopidogrel. This drug prevents blood clots, but is known to have a side-effect that can cause stomach bleeding. Consequently, many users are also prescribed a proton pump inhibitor (PPI). Now, however, a meta-analysis of almost 160,000 patients carried out at the Medical University of Vienna and Wilhelminenhospital, Vienna, has shown that simultaneous use of these drugs can increase the risk of cardiac damage.

31 Aug 2010

African-Americans at higher risk of developing stent thrombosis

African-American race is a distinct risk factor for developing life-threatening blood clots after receiving a drug-coated stent, according to research reported in Circulation: Journal of the American Heart Association.

31 Aug 2010

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Aspirin and thienopyridine antiplatelet therapy (such as clopidogrel) are standard care in the treatment of acute coronary syndrome (ACS) and even in stable coronary artery disease (CAD) after coronary intervention with stent. However, effective antiplatelet agents are needed which do not increase the risk of bleeding.

31 Aug 2010

Clopidogrel News and Research

POZEN presents PA32540 Phase 1 study results for cardiovascular disease at AHA Session

PPIs, antiplatelet drugs can help treat CV disease patients at high risk of upper GI bleeding

Researchers to determine levels of stroke risk in patients with narrowed brain arteries

Research Roundup: Basing insurance on results, not cost; Americans skeptical of public health efforts; seniors' comprehensive care

Eliminating copayments for high-value prescription drugs improves employees' adherence to treatment regimens

Study finds increasing dosage of blood thinners can help cardiovascular disease patients with genetic defect

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

Aspirin reduces risk of death from prostate cancer

Dual antiplatelet therapy study expanded into Australia and New Zealand

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

New guidelines feature various key updates for stroke or TIA survivors

CyDex terminates joint development agreement on Captisol-enabled clopidogrel with Prism Pharmaceuticals

New genetic screening program to reduce risk associated with Plavix

Biodegradable polymers represent future of stent design

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

Ticagrelor exhibits potential for prevention of heart attacks

Accumetrics secures $24 million in capital infusion

Using clopidogrel, PPIs increases cardiac damage risk: Study

African-Americans at higher risk of developing stent thrombosis

J-LANCELOT trial finds E5555 may reduce MACE without increasing serious bleeding events

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News